levofloxacin has been researched along with colchicine in 10 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (colchicine) | Trials (colchicine) | Recent Studies (post-2010) (colchicine) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 15,472 | 404 | 2,974 |
| Protein | Taxonomy | levofloxacin (IC50) | colchicine (IC50) |
|---|---|---|---|
| Tubulin alpha-1A chain | Sus scrofa (pig) | 3.7639 | |
| Tubulin beta chain | Sus scrofa (pig) | 3.8663 | |
| Tubulin beta-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta chain | Homo sapiens (human) | 2.7244 | |
| Tubulin alpha-3C chain | Homo sapiens (human) | 2.4334 | |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | 4.3 | |
| Tubulin alpha-1B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-4A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-4B chain | Homo sapiens (human) | 2.4334 | |
| Vesicular acetylcholine transporter | Tetronarce californica (Pacific electric ray) | 2.62 | |
| Tubulin beta-3 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2A chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-8 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Bos taurus (cattle) | 2.8255 | |
| Tubulin alpha-3E chain | Homo sapiens (human) | 2.4334 | |
| Tubulin alpha-1A chain | Homo sapiens (human) | 2.4334 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.0611 | |
| Similar to alpha-tubulin isoform 1 | Bos taurus (cattle) | 3.1553 | |
| Tubulin alpha-1C chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-6 chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-2B chain | Homo sapiens (human) | 2.4334 | |
| Tubulin beta-1 chain | Homo sapiens (human) | 2.4334 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Abuo-Rahma, GEA; Badr, M; Bass, AKA; El-Zoghbi, MS; Mohamed, MFA; Nageeb, EM | 1 |
2 review(s) available for levofloxacin and colchicine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Benzimidazoles; Cyclic Nucleotide Phosphodiesterases, Type 5; Daunorubicin; Doxorubicin; fms-Like Tyrosine Kinase 3; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Molecular Targeted Therapy; Morpholines; Nicotinamide Phosphoribosyltransferase; Nitric Oxide; Pyrimidines; Quinazolines; Structure-Activity Relationship; Transcription Factors | 2021 |
8 other study(ies) available for levofloxacin and colchicine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |